Patents Assigned to Asahi Kasei Pharma Corporation
-
Patent number: 7588910Abstract: There is provided a method for specifically determining a glycated ?-chain N-terminal of glycated hemoglobin using enzymes without a separation operation, and a determination reagent kit therefor. A protease that cleaves a glycated amino acid and/or a glycated peptide from a glycated ?-chain N-terminal without substantially cleaving a glycated amino acid or a glycated peptide from a glycated ?-chain N-terminal of glycated hemoglobin or a fragment thereof is screened. The method of specifically determining a glycated ?-chain N-terminal of glycated hemoglobin and the determination reagent kit are provided by using the protease obtained by the screening method. According to the present invention, a glycated ?-chain N-terminal of glycated hemoglobin can specifically be determined without a separation operation.Type: GrantFiled: May 21, 2004Date of Patent: September 15, 2009Assignees: Asahi Kasei Pharma Corporation, Ichibiki Co., Ltd.Inventors: Takeshi Matsuoka, Shinji Koga, Takuji Kouzuma, Issei Yoshioka, Atsuhisa Nishimura, Homare Itou, Toshihiko Kumazawa, Takashi Kuroyanagi
-
Patent number: 7582658Abstract: A novel compound represented by the following formula (1) or a salt thereof: wherein symbol “A” represents a saturated heterocyclic group, a 5-membered heteroaromatic group having two heteroatoms in the ring, a group represented by the formula A1 (R2, R3, and R4 represent hydrogen atom, hydroxyl group, etc.), etc., B represents a group represented by the formula B1 (R11 represents hydrogen atom, hydroxyl group, etc.), etc., R1 represents an alkyl group, and symbol “n” represents an integer of 2 to 6, which has a parathyroid hormone depressing action and showing low toxicity, and a medicament containing the compound or salt thereof as an active ingredient.Type: GrantFiled: December 23, 2004Date of Patent: September 1, 2009Assignee: Asahi Kasei Pharma CorporationInventors: Shiro Miyoshi, Toshinori Ishizuya
-
Publication number: 20090192154Abstract: A sultam derivative of Formula (1) described below having inhibitory action for aggrecanase activity is provided. The sultam derivative of Formula (1) and a salt thereof exhibit strong inhibitory action for aggrecanase activity in a living body of a mammalian animal including human, and is useful, for example, as an active ingredient of a pharmaceutical agent for preventing and/or treating various diseases caused by degradation of aggrecan.Type: ApplicationFiled: December 23, 2008Publication date: July 30, 2009Applicant: Asahi Kasei Pharma CorporationInventors: Naomi MAEKAWARA, Masakazu Atobe, Masashi Kawanishi, Eiichi Tanaka
-
Patent number: 7560478Abstract: In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. Crystals of any compound among 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, and methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate, and methods of producing the same are provided.Type: GrantFiled: July 19, 2007Date of Patent: July 14, 2009Assignee: Asahi Kasei Pharma CorporationInventors: Yuichi Arimoto, Naoyuki Ishii, Motoshi Shoda
-
Publication number: 20090156823Abstract: (S)-1-(4-Chloro-5-isoquinolinesulfonyl)-3-(methylamino)pyrrolidine monohydrochloride and a crystal thereof, and a crystal of the aforementioned monohydrochloride having a major peak or peaks at one or more positions selected from the group consisting of positions where 2?s are about 13.9°, 21.5°, 21.7°, 22.4°, 22.8°, 24.5° and 35.0° in a powder X-ray diffraction spectrum, which have excellent properties as active ingredient of a medicament for prophylactic and/or therapeutic treatment of glaucoma and the like.Type: ApplicationFiled: July 1, 2008Publication date: June 18, 2009Applicant: Asahi Kasei Pharma CorporationInventors: Hitoshi Kida, Koki Matsubara, Shunsuke Kaneko, Yoshihito Kanzawa
-
Patent number: 7531533Abstract: A compound represented by the general formula (I) or a salt thereof: [T represents oxygen atom and the like; V represents CH2 and the like; R01 to R04 represent hydrogen atom and the like; A represents a linear alkylene group or linear alkenylene group having 2 to 8 carbon atoms and the like; D represents carboxyl group and the like; X represents ethylene group, trimethylene group and the like; E represents —CH(OH)— group and the like; and W represent —U1—(RW1)(RW2)—U2—U3 group (U1 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; RW1 and RW2 represent hydrogen atom and the like; U2 represents a single bond, an alkylene group having 1 to 4 carbon atoms and the like; and U3 represent an alkyl group having 1 to 8 carbon atoms and the like), or a residue of a carbon ring or heterocyclic compound], which can be utilized as an active ingredient of medicaments effective for prophylactic and/or therapeutic treatment of skeletal diseases such as osteoporosis and fracture, glaucoType: GrantFiled: January 26, 2006Date of Patent: May 12, 2009Assignee: Asahi Kasei Pharma CorporationInventors: Motoshi Shoda, Toshinori Ishizuya
-
Publication number: 20090062530Abstract: A compound represented by the formula (I): [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.Type: ApplicationFiled: October 8, 2008Publication date: March 5, 2009Applicant: Asahi Kasei Pharma CorporationInventors: Motoshi Shoda, Hiroshi Kuriyama
-
Publication number: 20090054401Abstract: [Object] To provide a compound having prostaglandin production-suppressing action and leukotriene production-suppressing action. [Means for Solution] A compound represented by the formula (I): [In the formula, represents a single bond, or a double bond, Link represents a single bond, or a saturated or unsaturated straight hydrocarbon having 1 or 2 carbon atoms, W represents a single bond, oxygen atom, sulfur atom, N(Rw) etc., Rw represents hydrogen atom, an alkyl group having 1 to 8 carbon atoms etc, Rs represents -D-Rx etc., D represents a single bond, oxygen atom, sulfur atom etc., Rx represents a linear or branched saturated alkyl group having 3 to 8 carbon atoms etc., one of V1 and V2 represents Zx, and the other represents AR, Zx represents hydrogen atom, a linear or branched saturated alkyl group having 1 to 4 carbon atoms etc.Type: ApplicationFiled: March 30, 2007Publication date: February 26, 2009Applicant: Asahi Kasei Pharma CorporationInventors: Akiko Matsumoto, Motoshi Shoda, Hiroshi Kuriyama
-
Publication number: 20090048223Abstract: A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or —C(R3)(R4)— (R3 and R4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G4 represents hydroType: ApplicationFiled: February 27, 2008Publication date: February 19, 2009Applicant: Asahi Kasei Pharma CorporationInventors: Koki Matsubara, Atsushi Iesato, Akifumi Oomura, Koh Kawasaki, Rintaro Yamada, Minoru Seto
-
Publication number: 20090042279Abstract: It is intended to provide a noninvasive method of conveniently detecting mild impaired glucose tolerance and/or insulin hyposecretion at the early stage with the use of an enzyme. Namely, mild impaired glucose tolerance and/or insulin hyposecretion at the early stage are detected by quantifying myoinositol secreted into the urine before loading glucose and after loading glucose for a definite period of time with the use of a reagent and comparing the increase (or the increase ratio) in the myoinositol content thus measured with a characteristic level which has been preliminarily determined in normal subjects.Type: ApplicationFiled: October 9, 2008Publication date: February 12, 2009Applicant: Asahi Kasei Pharma CorporationInventors: Masaru YAMAKOSHI, Takuji Kouzuma
-
Patent number: 7470807Abstract: A compound represented by the formula (I): [In the formula, Link represents a saturated or unsaturated straight hydrocarbon chain having 1 to 3 carbon atoms, C2 to C6 in the aromatic ring (E) independently represent a ring-constituting carbon atom, one of the ring-constituting carbon atoms may be replaced with V, V represents nitrogen atom, or carbon atom substituted with Zx, Zx represents a saturated alkyl group having 1 to 4 carbon atoms and the like, Rs represents -D-Rx etc., D represents a single bond, oxygen atom and the like, Rx represents a saturated alkyl group having 3 to 8 carbon atoms and the like, AR represents a partially unsaturated or completely unsaturated condensed bicyclic carbon ring or a heterocyclic ring, and Y represents hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms and the like] or a salt thereof. A compound having prostaglandin production-suppressing action and leukotriene production-suppressing action is provided.Type: GrantFiled: August 13, 2004Date of Patent: December 30, 2008Assignee: Asahi Kasei Pharma CorporationInventors: Motoshi Shoda, Hiroshi Kuriyama
-
Publication number: 20080318256Abstract: Disclosed is a sugar and/or a sugar alcohol as a substance for suppressing dephosphorylation reaction of a phosphorylated coenzyme. Also disclosed is a method for stabilizing a phosphorylated coenzyme which is characterized by having at least a substance for suppressing dephosphorylation reaction of the phosphorylated coenzyme coexist with the phosphorylated coenzyme.Type: ApplicationFiled: October 5, 2005Publication date: December 25, 2008Applicant: ASAHI KASEI PHARMA CORPORATIONInventor: Fumitomo Odawara
-
Publication number: 20080319083Abstract: The object is to provide an SNRI-containing preparation which has a higher absorbability compared to a conventional SNRI preparation, produces its effect rapidly, and is readily administered to a patient who is hard to be administered via an oral route. Disclosed is a preparation for transmucosal administration, comprising a selective serotonin/noradrenaline reuptake inhibitor and a thickening agent.Type: ApplicationFiled: April 25, 2008Publication date: December 25, 2008Applicant: ASAHI KASEI PHARMA CORPORATIONInventor: Hideshi NATSUME
-
Publication number: 20080295259Abstract: Provided are a method of stabilizing a leuco dye storable as a liquid for a long time, a method of reducing nonspecific color development thereof at a time of a color development reaction, and a stable liquid reagent composition using the methods. The inventors of the present invention found that coexistence of the leuco dye with a specific reducing agent resulted in suppression of self color development and its remarkably improved stability in a solution, and that when a color development reaction of the leuco dye with hydrogen peroxide was performed, coexistence of the leuco dye, in a reaction solution, with another dye which had an absorption spectrum not influencing a measurement wavelength of the leuco dye and did not react with hydrogen peroxide suppressed nonspecific color development and lowered a reagent blank value, which was applied to an analytical reagent.Type: ApplicationFiled: February 21, 2008Publication date: December 4, 2008Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Shigeru UEDA, Takeshi MATSUOKA, Akihiko KAN
-
Patent number: 7452687Abstract: It is intended to provide a noninvasive method of conveniently detecting mild impaired glucose tolerance and/or insulin hyposecretion at the early stage with the use of an enzyme. Namely, mild impaired glucose tolerance and/or hyposecretion at the early stage are detected by quantifying myoinositol secreted into the urine before loading glucose and after loading glucose for a definite period of time with the use of a reagent and comparing the increase (or the increase ratio) in the myoinositol content thus measured with a characteristic level which has been preliminarily determined in normal subjects.Type: GrantFiled: March 27, 2003Date of Patent: November 18, 2008Assignee: Asahi Kasei Pharma CorporationInventors: Masaru Yamakoshi, Takuji Kouzuma
-
Publication number: 20080242660Abstract: An agent and composition for the prevention of and/or treatment for vasospasm accompanying a bypass operation, which contains as an active ingredient either a compound represented by the following general formula (I) or an acid addition salt or hydrate thereof. R1 represents a hydrogen atom or a hydroxyl group.Type: ApplicationFiled: January 27, 2005Publication date: October 2, 2008Applicant: ASAHI KASEI PHARMA CORPORATIONInventor: Hiroaki Shimokawa
-
Publication number: 20080234483Abstract: Fasudil-containing preparations that despite the us of a container excelling in the visibility of contents without particularly blocking of light, exhibit high stability against light; and a method of improving the stability of the preparations against light of storing the same. By regulating the pH value of aqueous solution of fasudil charged in a colorless transparent container to ?5.5, there can be provided fasudil-containing preparations excelling in stability against light; and can be provided a method of improving the stability of the aqueous solution of fasudil against light, or storing the same.Type: ApplicationFiled: March 4, 2005Publication date: September 25, 2008Applicant: ASAHI KASEI PHARMA CORPORATIONInventors: Takuji Maejima, Miki Ohshima
-
Publication number: 20080200535Abstract: There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.Type: ApplicationFiled: August 24, 2007Publication date: August 21, 2008Applicant: Asahi Kasei Pharma CorporationInventors: Yutaka Ohmori, Masakazu Komatsu
-
Publication number: 20080090767Abstract: The present invention is intended to provide a novel pharmaceutical agent having an excellent preventive effect on post-stroke RSD. The present invention provides an agent for preventing the onset of post-stroke RSD, comprising natural calcitonin or a calcitonin derivative as an active ingredient. The present invention is also intended to provide a method for preventing the onset of post-stroke RSD, comprising administering natural calcitonin or a calcitonin derivative and use of natural calcitonin or a calcitonin derivative for producing an agent for preventing the onset of post-stroke RSD.Type: ApplicationFiled: September 27, 2007Publication date: April 17, 2008Applicant: Asahi Kasei Pharma CorporationInventor: Satoru Matayoshi
-
Publication number: 20080070967Abstract: [Object] In the case of using 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, or methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate as a medicine, more preferable aspects or improved methods are provided. [Means] Crystals of any compound among 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionic acid, methyl 3-[4-(indan-2-yloxy)-3-(1-methyl-1H-indazol-5-yl)-5-nitrophenyl]propionate, and methyl 3-[3-amino-4-(indan-2-yloxy)-5-(1-methyl-1H-indazol-5-yl)phenyl]propionate, and methods of producing the same are provided.Type: ApplicationFiled: July 19, 2007Publication date: March 20, 2008Applicant: Asahi Kasei Pharma CorporationInventors: Yuichi Arimoto, Naoyuki Ishii, Motoshi Shoda